Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

NCT06508827 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Difficulty recruiting participants

Conditions

Anemia, Iron Deficiency
Melanoma

Interventions

DRUG: Iron dextran 1000 mg IV

Sponsor

Indiana University